Alx Oncology Holdings  (ALXO)

Alx Oncology Holdings  (ALXO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $173M; returns 1 day -1.7%, 1 week +10.4%, 1 year -33.1%.

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company primarily focused on developing novel immuno-oncology therapies to treat various cancers. The company's core strategy revolves around two main product candidates. Its lead candidate is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein.

Groups ALXO belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Immunotherapy
• Healthcare
• Cancer Therapeutics
• Biopharmaceutical
• Clinical Stage
• Antibody-Drug Conjugates

ALXO financial model: income statement, cash flow and balance sheet